Medical Oncologist
Hyderabad's Dedicated Thyroid Cancer Network · NCCN protocols · 11 city centres + 35 partner centres
Best Thyroid Cancer Hospital in Hyderabad — 11 Centres, NCCN Protocols, NABH-Accredited Partners
Thyroid cancer has one of the best prognoses in all of oncology — most patients with the common papillary and follicular subtypes live a completely normal lifespan after appropriate treatment. But the quality of that treatment depends on three things: a surgical team experienced enough to protect the nerve that controls your voice and the small glands that regulate your calcium, access to radioactive iodine therapy at a NABH-accredited nuclear medicine partner, and an endocrinology service that will manage your thyroid hormone replacement and follow-up for life. CION runs Hyderabad's dedicated thyroid cancer network: 11 city centres, NCCN-protocol care for thyroid cancer, integrated endocrinology, and NABH-accredited partners for surgery and radioactive iodine therapy.
- NCCN-protocol thyroid care — Tumour-board review with ATA risk stratification on every case
- NABH-accredited partners — Verified endocrine surgery and radioactive iodine therapy pathways
- Lifelong follow-up close to home — TSH suppression and thyroglobulin surveillance across 11 centres
- Free written second opinion — Worth ₹950 — yours to keep, take anywhere
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The CION Thyroid Cancer Panel
Endocrine surgery, medical oncology & RAI coordination — under one team.
Surgical, medical, and radiation oncology — with radioactive iodine therapy coordinated through NABH-accredited nuclear medicine partners. An endocrine surgeon or surgical oncologist leads thyroidectomy; an endocrinologist manages lifelong TSH suppression; a medical oncologist takes over for advanced or RAI-refractory cases.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Why the hospital you choose decides everything
Why the hospital matters more than the building
Most patients begin by searching for the best thyroid cancer doctor in Hyderabad. The doctor matters — but thyroid cancer treatment is a partnership between a surgeon, an endocrinologist, and a nuclear medicine team, with a relationship that extends across your lifetime. The central technical signals are whether the surgeon performs enough thyroidectomies each year to confidently protect the recurrent laryngeal nerve (which controls voice) and the parathyroid glands (which regulate calcium), whether radioactive iodine therapy is available via a verified partner pathway when indicated, and whether the hospital provides the lifelong follow-up that thyroid cancer requires. The good news: with the right team, the outcomes are excellent — 5-year survival for the common types of thyroid cancer exceeds 95%.
This page gives you an honest framework — eight institutional signals that separate hospitals that can manage thyroid cancer well from hospitals that simply offer the service — and explains how CION is built around them. Use the framework on every hospital you shortlist. If a hospital can't answer in writing, it should fall off your list.
Did you know?
Most thyroid cancers — particularly the papillary and follicular types that make up about 85–90% of cases — have an excellent prognosis with 5-year survival exceeding 95%. Modern treatment with thyroidectomy followed by radioactive iodine therapy when indicated, plus lifelong thyroid hormone replacement, allows most patients to live a completely normal lifespan. Even patients with disease that has spread to neck lymph nodes typically have outcomes close to those with localised disease — thyroid cancer is among the most treatable cancers in oncology when managed correctly. (Source: NCI SEER, 5-year relative survival.)
11 CION centres across Hyderabad · 35+ partner centres across Telangana & AP
CION cancer care is closer than you think.
Ultrasound, FNAC, blood tests, TSH monitoring, hormone dose adjustments, and clinical follow-up happen at the centre nearest you — for decades. Complex thyroidectomy, neck dissection, and radioactive iodine therapy run through NABH-accredited partners with verified endocrine surgical and nuclear medicine expertise. Same panel, same protocols, same tumour board at every site.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
The 8-criteria decision framework
8 things that make a hospital genuinely the best for thyroid cancer in Hyderabad
These are the eight institutional signals that matter most for thyroid cancer. Each is verifiable. Each is non-negotiable. Ask the question, get it in writing, and walk away if you can't.
An endocrine surgery and endocrinology-led multidisciplinary team
Thyroid cancer treatment combines surgery, radioactive iodine therapy when indicated, lifelong thyroid hormone replacement, and (for the small subset who need it) targeted-therapy pills. The team needs an endocrine surgeon or surgical oncologist trained specifically in thyroid surgery, an endocrinologist who will manage your thyroid hormone replacement and TSH levels for life, a nuclear medicine physician who supervises radioactive iodine therapy at a partner facility, a medical oncologist for advanced cases requiring targeted therapy, a pathologist with experience in thyroid cancer subtyping and molecular testing (BRAF, RET, TERT), and a genetic counsellor for medullary thyroid cancer where inherited gene mutations are common.
Walk away if the hospital cannot name who will manage your TSH levels and lifelong follow-up.
Tumour-board review with risk stratification and molecular results
A thyroid cancer tumour board reviews the FNAC findings, ultrasound features, tumour size and extent, lymph node involvement, and molecular test results (particularly BRAF for papillary cancers and RET for medullary cancers). The board assigns an ATA risk stratification — a structured assessment that places patients into low, intermediate, or high-risk groups based on tumour size, spread, and molecular features. This risk group determines whether you need a total thyroidectomy or just a lobectomy (removal of half the thyroid), whether radioactive iodine therapy is recommended, and how aggressively TSH should be suppressed in follow-up.
Walk away if surgery is recommended without a documented discussion of the ATA risk group and the rationale for total vs partial thyroidectomy.
Annual thyroidectomy volume with nerve and parathyroid preservation
Thyroid surgery has a strong volume-outcome relationship — high-volume thyroid surgeons demonstrate dramatically lower rates of permanent voice damage (from injury to the recurrent laryngeal nerve, which runs immediately behind the thyroid) and permanent low calcium (from injury to the four small parathyroid glands sitting on the back of the thyroid). The best surgeons use intraoperative nerve monitoring to verify the nerve is functioning throughout the operation, and carefully preserve or auto-transplant the parathyroid glands. Ask: 'How many thyroidectomies did your team perform last year? Do you routinely use intraoperative nerve monitoring? What is your rate of permanent voice change and permanent low calcium?' Specific numbers indicate transparency.
Walk away if the surgeon doesn't use intraoperative nerve monitoring as a routine technique.
Ultrasound, FNAC, and molecular testing infrastructure
Thyroid cancer is diagnosed by ultrasound (using a structured scoring system called TI-RADS to classify nodules) followed by fine needle aspiration cytology (FNAC) of suspicious lesions, reported using a standardised classification called the Bethesda system. Once cancer is confirmed, thyroglobulin (a blood tumour marker for differentiated thyroid cancer), calcitonin (a blood marker specific to medullary thyroid cancer), and molecular tests for BRAF V600E, RET, and TERT promoter mutations guide treatment decisions. For medullary thyroid cancer, RET gene testing is essential because around 25% are inherited (linked to a syndrome called MEN2) and family members may need testing.
Walk away if the hospital does not run molecular testing or cannot explain how your specific cancer subtype affects treatment.
NABH-accredited partner pathway for radioactive iodine therapy
Radioactive iodine (also called RAI or I-131) is a treatment unique to thyroid cancer — taking advantage of the fact that thyroid cells and most differentiated thyroid cancer cells absorb iodine. After total thyroidectomy, a dose of radioactive iodine is given as a capsule or drink to destroy any remaining thyroid tissue and treat microscopic cancer cells. This treatment requires a specialised nuclear medicine facility with isolation rooms because patients emit low levels of radiation for a few days. Not every patient needs RAI — the decision is risk-based — but when indicated, it's a uniquely effective treatment.
Walk away if the hospital cannot name the NABH-accredited nuclear medicine facility that delivers RAI therapy.
Day-care targeted therapy capability for advanced cases
A small subset of thyroid cancer patients — those whose disease progresses beyond radioactive iodine therapy (called RAI-refractory), patients with advanced medullary thyroid cancer, or those with the rare and aggressive anaplastic subtype — benefit from modern targeted-therapy pills. For RAI-refractory differentiated thyroid cancer: lenvatinib and sorafenib. For medullary thyroid cancer with RET gene mutations: selpercatinib and pralsetinib — newer drugs that are highly effective. For BRAF V600E-mutant anaplastic thyroid cancer: dabrafenib + trametinib combination. These are oral medications taken at home but require regular oncologist review.
Walk away if the hospital cannot run the molecular testing needed to identify candidates for these targeted treatments.
Insurance, ArogyaSri, and TPA empanelment in writing
Thyroid cancer treatment is generally less expensive than many other cancers, but the lifelong nature of follow-up means costs add up — surgery, possibly RAI therapy, lifelong medication, and regular blood tests and ultrasounds for years. Targeted therapy for the advanced subset is significantly more expensive. A hospital that isn't empanelled for your insurance or ArogyaSri at the specific centre where your procedure happens can derail planning.
Walk away if cost estimates change after admission — a serious hospital writes them down beforehand.
Lifelong follow-up for TSH suppression and tumour marker surveillance
Thyroid cancer survivors require lifelong follow-up — far longer than for most other cancers. After total thyroidectomy, you take a thyroid hormone replacement pill (levothyroxine) every morning for the rest of your life, with the dose adjusted to keep the thyroid-stimulating hormone (TSH) at specific targets (very low for higher-risk patients to suppress any remaining thyroid cells, moderate for low-risk patients). Surveillance includes regular thyroglobulin or calcitonin blood tests, periodic neck ultrasound, and clinical examination. This is a long-term partnership with your team.
Walk away if you're told you must travel to one campus for every routine TSH check and ultrasound for the next twenty years.
We mean it: take this framework to any consultation — ours or anyone else's. A hospital worth choosing will welcome these questions.
Hospital archetype comparison
Cancer-specialty network vs multi-specialty vs Ayurveda — which is structurally right for thyroid cancer?
Hyderabad has all three models. They are not interchangeable. The right one depends on whether you have access to a high-volume endocrine surgeon, a reliable RAI partner pathway, and an endocrinology service for lifelong follow-up. Here's an honest comparison.
| Hospital archetype | Strengths for thyroid cancer | Trade-offs | Best fit for |
|---|---|---|---|
| Dedicated cancer-specialty hospital or network | Tumour-board review with ATA risk stratification. Established molecular testing pathways. Network for lifelong follow-up near home. Targeted-therapy capability for advanced cases. Partner pathway for surgery and radioactive iodine. | Surgery and RAI therapy coordinated through partners. Strong networks solve this with NABH-accredited tie-ups. | Most thyroid cancer patients — across all risk groups where multidisciplinary coordination and lifelong follow-up close to home matter. |
| Multi-specialty general hospital with in-house endocrine surgery | In-house endocrine surgery team if high-volume. In-house endocrinology service. Single-campus coordination across surgery and ongoing care. | Nuclear medicine RAI facility availability must be verified. Molecular testing turnaround varies. Access to advanced targeted therapy varies. | Patients prioritising single-campus care if and only if the hospital has both high-volume endocrine surgery and in-house RAI facility. |
| Ayurveda hospital | Symptom palliation and post-treatment recovery support. Some patients value the holistic framing. | Not evidence-based as primary curative treatment. Should never replace surgery or radioactive iodine therapy in thyroid cancer. | Strictly as an add-on to allopathic oncology care. Discuss any Ayurveda use openly with your endocrinologist — some herbal preparations interact with thyroid hormone medication. |
The structurally correct default for most thyroid cancer patients is a dedicated cancer-specialty hospital or network with NABH-accredited partners for surgery and radioactive iodine therapy, plus integrated endocrinology for lifelong follow-up. This is precisely how CION is built.
Why CION — institutional answer
How CION is built for thyroid cancer at an institutional level
CION is not a single hospital. It is a dedicated cancer-specialty network — 11 centres across Hyderabad and 35+ partner centres across Telangana and Andhra Pradesh — with the same panel of oncologists, the same NCCN protocols, and the same tumour-board governance at every site. The network is architected specifically around the eight signals above.
A network architecture, not a building
Hospital infrastructure for thyroid cancer is tiered at CION. Ultrasound, FNAC, blood tumour marker tracking (thyroglobulin or calcitonin), TSH monitoring, hormone dose adjustments, and clinical follow-up happen at the centre nearest your home — for decades, not just months. Total thyroidectomy with nerve and parathyroid preservation, central or lateral neck dissection, robotic and minimally invasive thyroidectomy, and radioactive iodine therapy run through NABH-accredited partner hospitals with verified endocrine surgical and nuclear medicine expertise. The same oncology team that consults at one centre stays with you across the network.
Ultrasound, FNAC, and complete molecular workup
Thyroid ultrasound with structured TI-RADS classification, fine needle aspiration cytology (FNAC) reported using the Bethesda system, thyroglobulin and calcitonin testing, and molecular testing for BRAF V600E (common in papillary cancer), RET (essential for medullary cancer), and TERT promoter mutations (an aggressive marker) are all available through integrated lab pathways at CION. For medullary thyroid cancer, germline RET testing identifies patients with inherited MEN2 syndrome — important because family members may also need testing and preventive thyroidectomy.
Genetic counselling for hereditary thyroid cancer
Approximately 25% of medullary thyroid cancers are inherited as part of an inherited cancer syndrome called multiple endocrine neoplasia type 2 (MEN2), caused by RET gene mutations. CION arranges RET genetic testing and counselling for all medullary thyroid cancer patients and their at-risk family members. Children identified as RET mutation carriers may need preventive thyroidectomy before cancer develops — a powerful preventive intervention. A small number of papillary and follicular thyroid cancers also have hereditary components (such as familial papillary thyroid cancer or Cowden syndrome) and benefit from genetic evaluation.
NCCN-protocol surgical and medical care at every centre
All 11 CION centres in Hyderabad provide pre-surgical evaluation, post-surgical follow-up, and targeted-therapy pills for advanced cases — lenvatinib and sorafenib for differentiated thyroid cancer that no longer responds to radioactive iodine, selpercatinib and pralsetinib for medullary thyroid cancer with RET mutations, and dabrafenib + trametinib for BRAF V600E-mutant anaplastic thyroid cancer. Oncology-trained nursing, infusion capability when needed, and on-site oncologist supervision are standard at every centre.
NABH-accredited partner network for surgery and radioactive iodine
Where a thyroid cancer case requires total thyroidectomy with intraoperative nerve monitoring, total thyroidectomy with central or lateral neck dissection, robotic thyroidectomy (less commonly used in India but available for selected cases), or radioactive iodine therapy with isolation room facilities, CION coordinates the procedure through NABH-accredited partner hospitals with established endocrine surgery programs and nuclear medicine departments. NABH accreditation ensures audited compliance with patient-safety, infection-control, surgical safety, and radiation safety protocols.
Lifelong endocrinology follow-up and supportive care
Thyroid cancer survivors take a thyroid hormone replacement pill every morning for life, with periodic dose adjustments to maintain TSH at specific targets. Beyond hormone replacement, surveillance includes regular thyroglobulin or calcitonin testing depending on cancer type, periodic neck ultrasound for the first several years, clinical examination, calcium monitoring (especially in the first year after surgery), and bone density monitoring in patients on long-term TSH suppression. Family screening for hereditary cases, fertility counselling for young patients planning pregnancy on thyroid hormone replacement, and management of pregnancy-related thyroid dose changes are all part of the CION pathway.
Tumour-board governance on every thyroid cancer case
Every thyroid cancer case at CION is reviewed by the multidisciplinary tumour board before the treatment plan is finalised. The board debates the surgical extent (total thyroidectomy vs lobectomy), the type of lymph node dissection, the ATA risk group, the rationale for or against radioactive iodine therapy, TSH suppression targets for follow-up, and biomarker-driven targeted therapy decisions for advanced cases. The board produces a written summary that becomes part of your records — and yours to keep. You can take it to any second opinion, anywhere.
Network proof — outcomes and credentials
CION's institutional numbers — verifiable, not adjectival
Specifics beat vague claims. Here is the verifiable network footprint behind CION's thyroid cancer pathway.
| Network metric | CION figure |
|---|---|
| City centres in Hyderabad | 11 |
| Partner centres across Telangana & Andhra Pradesh | 35+ |
| Centres with CT, MRI & PET-CT diagnostics | 6 |
| Centres with thyroid ultrasound and FNAC | All 11 city centres |
| Cancer specialists on panel | 17+ |
| Patients treated network-wide | 15,000+ |
| Thyroid cancer cases managed annually | 1,000+ per year |
| Google review rating | 4.8★ (800+ reviews) |
| Endocrine surgery and radioactive iodine partner accreditation | NABH-accredited |
| Molecular testing (BRAF, RET, TERT) on relevant cases | Integrated lab pathway |
| Tumour-board review with ATA risk stratification | Written summary provided |
| Lifelong follow-up close to home | All 11 centres |
| Written second opinion | Free (worth ₹950) |
| Insurance and ArogyaSri | Empanelled |
| EMI facility for self-paying patients | Selected packages |
Financial accessibility
Insurance, ArogyaSri, and cost transparency
Thyroid cancer treatment costs are generally lower than those of many other cancers — but the lifelong nature of follow-up means medications and surveillance blood tests add up over the years. For the small subset of patients needing targeted therapy, costs increase substantially. Financial clarity at the start is part of clinical care, not separate from it. CION provides a written, itemised treatment plan and cost estimate before any decision is finalised.
ArogyaSri empanelment
Eligible patients can access state-scheme coverage at empanelled CION centres.
Cashless insurance
Most major insurers and TPAs accepted, with pre-authorisation handled by the CION insurance desk.
EMI facility
Available for self-paying patients on selected treatment packages.
Written cost estimate
Surgery, RAI therapy, lifelong levothyroxine, surveillance blood tests, ultrasounds, and targeted therapy if needed — itemised before treatment begins.
Radioactive iodine therapy and targeted-therapy drugs in particular have specific scheme rules. The CION insurance desk will confirm coverage and pre-authorisation requirements before your treatment begins. Ask for written confirmation.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Frequently asked questions about choosing a thyroid cancer hospital in Hyderabad
Which is the best thyroid cancer hospital in Hyderabad?
No single hospital is automatically best — and for thyroid cancer, the most important factors are whether the surgical team has high annual thyroidectomy volume with strong recurrent laryngeal nerve preservation rates (to protect voice) and parathyroid preservation (to protect calcium regulation), whether radioactive iodine therapy is available via a verified NABH-accredited partner pathway, and whether an endocrinology service provides lifelong follow-up. CION Cancer Clinics meets these criteria with 11 centres across Hyderabad and 1,000+ thyroid cancer cases managed every year.
How do I choose the right thyroid cancer hospital in Hyderabad?
Verify eight signals in writing: endocrine surgery and endocrinology-led multidisciplinary team, tumour-board review with ATA risk stratification and molecular results, annual thyroidectomy volume with intraoperative nerve monitoring and parathyroid preservation, ultrasound and FNAC with thyroglobulin/calcitonin and molecular testing infrastructure, NABH-accredited partner pathway for radioactive iodine therapy, day-care targeted therapy capability for advanced cases, insurance and ArogyaSri empanelment, and continuity of care for lifelong TSH suppression management and tumour marker surveillance.
What is the success rate of thyroid cancer treatment in Hyderabad?
Thyroid cancer outcomes are among the best in all of oncology — particularly for the differentiated types (papillary and follicular) that account for 85–90% of cases. Per US National Cancer Institute SEER data, 5-year relative survival for thyroid cancer overall is approximately 98% — close to 100% for localised disease, 98% for regional spread, and around 54% for distant spread (the lower figure mainly reflects rare anaplastic cases). Most patients with differentiated thyroid cancer live a completely normal lifespan with modern treatment: surgery, radioactive iodine therapy when indicated, and lifelong thyroid hormone replacement.
How much does thyroid cancer treatment cost in Hyderabad?
Costs vary by surgery extent and risk group. Indicative ranges: total thyroidectomy ₹1.5–3 lakh; lobectomy (removal of one lobe) ₹1–2.5 lakh; total thyroidectomy with central neck dissection ₹2–3.5 lakh; total thyroidectomy with lateral neck dissection ₹3–5 lakh; robotic or minimally invasive thyroidectomy ₹3–5 lakh (via NABH-accredited partner); radioactive iodine therapy ₹50,000–1.5 lakh per dose (via NABH-accredited partner, varies by dose); lenvatinib (for RAI-refractory cases) ₹40,000–60,000 per month; selpercatinib (for RET-mutant medullary thyroid cancer) ₹2–3 lakh per month; lifelong levothyroxine ₹100–500 per month; thyroid ultrasound with FNAC ₹3,500–8,500; BRAF and RET molecular testing ₹15,000–35,000. CION provides a written treatment plan and itemised cost estimate before treatment begins, with an EMI facility available on selected packages.
Should I choose a cancer-specialty hospital or a multi-specialty hospital for thyroid cancer?
Thyroid cancer is a long-term condition — you will see your team for the rest of your life for hormone monitoring and tumour marker surveillance. The key questions are: does the hospital have an endocrine or surgical oncologist with high thyroid surgery volume, an endocrinologist for lifelong TSH suppression management, and a verified partner pathway for radioactive iodine therapy? A cancer-specialty hospital or network usually offers tighter oncology coordination including molecular testing and access to advanced targeted therapy for the small subset of patients who need it. A multi-specialty general hospital with strong endocrine surgery and endocrinology can also work well. The structural fit for most thyroid cancer patients is the cancer-specialty pathway with NABH-accredited RAI partners and integrated endocrinology.
Is radioactive iodine (RAI) therapy available for thyroid cancer in Hyderabad?
Yes. Radioactive iodine (also called RAI or I-131) therapy is a treatment unique to thyroid cancer, taking advantage of the fact that thyroid cells (and most differentiated thyroid cancer cells) selectively absorb iodine. After total thyroidectomy, a dose of radioactive iodine is taken as a capsule or drink to destroy any remaining thyroid tissue including microscopic cancer cells. The treatment requires a specialised nuclear medicine facility with isolation rooms because patients emit low levels of radiation for a few days. CION coordinates RAI therapy through NABH-accredited partner nuclear medicine facilities, with the CION team managing pre-treatment preparation including TSH stimulation and post-treatment follow-up.
Is targeted therapy available for advanced thyroid cancer in Hyderabad?
Yes. For the small subset of thyroid cancer patients whose disease has progressed beyond radioactive iodine therapy, modern targeted-therapy pills are available in Hyderabad. For RAI-refractory differentiated thyroid cancer: lenvatinib and sorafenib (multikinase inhibitor pills). For medullary thyroid cancer with RET gene mutations: selpercatinib and pralsetinib (highly effective newer drugs). For BRAF V600E-mutant anaplastic thyroid cancer: dabrafenib + trametinib combination. CION arranges full molecular testing (BRAF, RET, TERT, NTRK) to identify patients who will benefit from these targeted therapies, and administers them with regular oncologist review.
Do thyroid cancer hospitals in Hyderabad accept ArogyaSri and private insurance?
Many qualified hospitals are empanelled for ArogyaSri and most major cashless insurers — but empanelment varies by centre and by procedure. Radioactive iodine therapy and targeted-therapy drugs in particular have specific scheme rules. CION Cancer Clinics is empanelled for ArogyaSri and accepts most major cashless insurance providers and TPAs. Request a written cost estimate and confirm pre-authorisation before treatment begins, especially for thyroidectomy with neck dissection and RAI therapy.
Are thyroid cancer hospitals in Hyderabad NABH accredited?
Several Hyderabad hospitals hold NABH accreditation — the Indian healthcare quality standard covering patient safety, infection control, and clinical governance. CION's partner hospitals for thyroidectomy, robotic and minimally invasive thyroid surgery, and radioactive iodine therapy facilities are NABH-accredited, giving patients audited assurance on infection control, surgical safety, and radiation safety protocols.
What facilities should I check before admitting for thyroid cancer surgery?
Confirm in writing: endocrine surgeon or surgical oncologist with high annual thyroid surgery volume, intraoperative recurrent laryngeal nerve monitoring (to protect voice), parathyroid preservation technique with intraoperative parathyroid identification, neck ultrasound with FNAC and TI-RADS classification capability, thyroglobulin and calcitonin lab turnaround, BRAF and RET molecular testing availability, ICU access if needed, NABH-accredited partner pathway for radioactive iodine therapy if RAI is recommended, endocrinology service for lifelong TSH suppression management, room categories, and a clear written cost estimate.
Your thyroid cancer team is one call away
Free 45-minute consultation with a senior CION oncologist. Tumour-board review with ATA risk stratification. NABH-accredited endocrine surgery and radioactive iodine partner pathway. Lifelong endocrinology follow-up across 11 Hyderabad centres. Free written second opinion — yours to keep, take anywhere. ArogyaSri, EMI, and cashless insurance accepted.
The information on this page is provided for general educational purposes and reflects current clinical practice in thyroid cancer oncology at the time of last medical review. It is not a substitute for individual medical advice, diagnosis, or treatment. Treatment decisions, drug choices, dosing, surgical approach, and follow-up schedules must be made by a qualified physician evaluating the specific patient. Survival statistics cited are population-level estimates drawn from public registries and do not predict outcomes for an individual case. Always discuss your specific situation with a qualified medical or surgical oncologist before acting on any information presented here. Last Medically Reviewed: May 2026 by Dr. Muralidhar Muddusetty — Surgical Oncologist.